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Abstract 
Background: US and European guidelines diverge on whether to vaccinate adults who are not at high risk for car-
diovascular events against influenza. Here, we investigated the associations between influenza vaccination and risk for 
acute myocardial infarction, stroke and pulmonary embolism during the 2009 pandemic in Norway, when vaccination 
was recommended to all adults.
Methods: Using national registers, we studied all vaccinated Norwegian individuals who suffered AMI, stroke, or pul-
monary embolism from May 1, 2009 through September 30, 2010. We defined higher-risk individuals as those using 
anti-diabetic, anti-obesity, anti-thrombotic, pulmonary or cardiovascular medications (i.e. individuals to whom vacci-
nation was routinely recommended); all other individuals were regarded as having lower-risk. We estimated incidence 
rate ratios with 95% CI using conditional Poisson regression in the pre-defined risk periods up to 180 days following 
vaccination compared to an unexposed time-period, with adjustment for season or daily temperature.
Results: Overall, we observed lower risk for cardiovascular events following influenza vaccination. When stratified 
by baseline risk, we observed lower risk across all three outcomes in association with vaccination among higher-risk 
individuals. In this subgroup, relative risks were 0.72 (0.59–0.88) for AMI, 0.77 (0.59–0.99) for stroke, and 0.73 (0.45–1.19) 
for pulmonary embolism in the period 1–14 days following vaccination when compared to the background period. 
These associations remained essentially the same up to 180 days after vaccination. In contrast, the corresponding rela-
tive risks among subjects not using medications were 4.19 (2.69–6.52), 1.73 (0.91–3.31) and 2.35 (0.78–7.06).
Conclusion: In this nationwide study, influenza vaccination was associated with overall cardiovascular benefit. This 
benefit was concentrated among those at higher cardiovascular risk as defined by medication use. In contrast, our 
results demonstrate no comparable inverse association with thrombosis-related cardiovascular events following 
vaccination among those free of cardiovascular medications at baseline. These results may inform the risk–benefit bal-
ance for universal influenza vaccination.
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Introduction
Influenza is a major trigger of cardiovascular events, and 
individuals with cardiovascular disease are at higher risk 
of influenza complications [1]. As a consequence, indi-
viduals at high cardiovascular risk, such as those with 
a history of cardiovascular diseases, diabetes or severe 
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obesity, are advised to receive preventative influenza vac-
cination annually [2].
Although, a vaccination might trigger coagulation 
abnormalities [3, 4], studies showed that the benefits 
via preventing influenza clearly outweighs any adverse 
effects among individuals at high cardiovascular risk 
[5–11]. However, whether the benefits of the vaccine on 
cardiovascular events extend across the spectrum of car-
diovascular risk are largely unknown.
The current US and European guidelines diverge on 
whether those who are apparently not at high risk should 
or should not be vaccinated. The Centers for Disease 
Control and Prevention in the US recommends that 
generally everyone six months of age and older should 
receive a vaccine [12]. In contrast, European [13] and 
other international guidelines [14–17] are more restric-
tive and advise vaccination only for those with special 
conditions, including high cardiovascular risk. However, 
none of these guidelines are based on strong evidence 
regarding those at lower cardiovascular risk.
In 2009, amongst fears of the pandemic influenza 
A(H1N1) and in contradiction to previous years, authori-
ties recommended that the whole Norwegian popula-
tion over 6 months of age undergo vaccination [18]. The 
vaccine was offered free of charge to all Norwegians. 
The high participation rate in the mass vaccination pro-
gram [19] allowed us to examine the occurrence of acute 
myocardial infarction, stroke and pulmonary embolism 
following influenza vaccination among those who were 




To minimize the risk of bias by unmeasured confound-
ing, we used the self-controlled case series (SCCS) 
method. The SCCS method compares incidence of events 
across different risk periods following exposure with inci-
dence during a baseline period. In SCCS design, cases act 
as their own controls in the baseline period when they 
are not exposed to vaccination. The SCCS method has 
the advantage of implicitly adjusting for all measured and 
unmeasured time invariant confounders, and it is con-
sidered as a standard method to study acute or triggering 
effects of transient exposures like vaccinations [20, 21].
Study population
We used the Norwegian Patient Registry [22] to iden-
tify patients aged 18 years or over hospitalized for AMI, 
stroke or pulmonary embolism. AMI cases were identi-
fied using ICD-10 codes I21 (“acute myocardial infarc-
tion”) or I22 (“subsequent myocardial infarction”). Stroke 
cases were identified using ICD codes I61 (“intracerebral 
haemorrhage”), I63 (“cerebral infarction”) or I64 (“stroke, 
not specified as haemorrhage or infarction”). pulmonary 
embolism was defined by ICD code I26 (“pulmonary 
embolism”). To increase the specificity of the diagnoses, 
only primary diagnoses were included, and for stroke, we 
only included those cases with an emergency hospitaliza-
tion, as previously recommended [23]. For all outcomes, 
we used the day of hospitalization as the date of event, 
and only the first episode of each event during the study 
period, i.e., from May 1, 2009 through September 30, 
2010 was considered in our analysis. We did not include 
any repeated events as cardiovascular events tend to 
cluster within the same individual.
Exposure information (influenza pandemic vaccine)
The exposure of interest was ‘Pandemrix’, a monovalent 
pandemic strain vaccine containing the oil-in-water adju-
vant AS03, manufactured by GlaxoSmithKline. Informa-
tion on date of vaccination was extracted from National 
Immunisation Registry and linked to the same individ-
ual’s previous and subsequent patient records using the 
Norwegian personal identification number. Generally, a 
single dose of Pandemrix was recommended. However, 
for those who received two doses, exposure was defined 
as the date of the first dose. The peak pandemic wave in 
Norway occurred between October 1, 2009 and Decem-
ber 31, 2009 [24]. The vaccination campaign began on 
October 19, 2009, and about 95% of the pandemic vac-
cinations were administered before December 31, 2009. 
The vaccination period overlapped with the peak period 
of the pandemic wave, but a small number of vaccines 
were also distributed after the peak pandemic wave. [24, 
25]
Identification of individuals at higher or lower risk 
for cardiovascular events
Because we did not have information on actual risk factor 
levels, we used medication use as a proxy for cardiovas-
cular risk status. Information on drugs dispensed before 
the date of vaccination according to the Norwegian Pre-
scription Database was used to define patients at higher- 
or lower-cardiovascular risk. All Norwegian pharmacies 
report every prescribed drug dispensed since January 
1, 2004 together with the patients’ Norwegian personal 
identification number to this database. Patients who 
were dispensed any of the following drugs: anti-diabetic 
drugs (ATC code: A10), anti-obesity drugs (ATC code: 
A08), anti-thrombotic drugs (ATC code: B01), glycosides 
(ATC code: C01A), anti-arrhythmic drugs (ATC code: 
C01B), nitrates (ATC code: C01D), beta-blockers (ATC 
code: C07), calcium channel blockers (ATC code: C08), 
anti-hypertensive drugs (ATC code: C02), diuretics (ATC 
code: C03), peripheral vasodilators or other vasodilators 
Page 3 of 11Sen et al. BMC Cardiovasc Disord           (2021) 21:31  
(ATC code: C04), drugs acting on the renin-angiotensin 
system, vasoprotective drugs (ATC code: C05), lipid mod-
ifying agents (ATC code: C10) and drugs for obstructive 
airway diseases (ATC code: R03) were regarded as being 
at higher risk for cardiovascular events. In the absence of 
prescriptions for these drugs, we regarded participants as 
being at lower cardiovascular risk.
Statistical analysis
For each individual, the observation period started from 
May 1, 2009 through September 30, 2010, or date of 
emigration or death (which ever came first). Only indi-
viduals who experienced a cardiovascular event and were 
vaccinated during the study period were included. Only 
individuals who experienced a cardiovascular event and 
were vaccinated during the study period were included. 
Exposed person time was categorised into the follow-
ing risk windows: (1) from 1 to 14  days before being 
vaccinated (pre-vaccination ‘risk’ period), (2) from 1 to 
14  days after vaccination, (3) from 15 to 28  days after 
vaccination, (4) from 29 to 59  days after vaccination, 
(5) from 60 to 90  days after vaccination, (6) from 91 to 
120 days after vaccination and (7) from 120 to 180 days 
after vaccination. All remaining time within the obser-
vation period was used as background period (unex-
posed person-time), to which the exposed risk-windows 
were compared. The unexposed person-time may have 
occurred before or after vaccination within the observa-
tion period. Each vaccinated case contributed to both 
exposed and unexposed person-times, and the incidence-
rate ratio was calculated by comparing the rate of AMI, 
stroke and pulmonary embolism experienced during risk 
periods (exposed person-time) following pandemic vac-
cination with the rate of these events during baseline 
periods (unexposed person-time) using conditional Pois-
son regression models. A pictorial presentation of SCCS 
study observation period is present in Fig. 1.
We excluded cases where the date of vaccination and 
date of event was on the same day as it was not clear 
which happened first. We present the number of these 
cases in Tables 2, 3 and Additional file 1: etable 1–6. As 
both cardiovascular events and influenza cases show 
seasonal variation, we adjusted for calendar period by 
dividing the risk periods into three calendar seasons (Jan-
uary-March; April-August and September-December) 
which reflect Norwegian seasons. All analyses were con-
ducted separately and together for both higher- or lower-
risk group defined based on medication use.
We also performed sensitivity analyses by controlling 
for daily mean temperature as a time-variant confounder. 
We extracted daily mean temperature from north, east, 
west, south and central regions of Norway from the 
webpage of the Norwegian Meteorology Institute and 
adjusted for temperature instead of calendar season in 
these additional analyses. In addition, we also performed 
sensitivity analyses including (1) both higher- and lower-
risk group together, (2) 1–59 days as the pre-vaccination 
interval, (3) 15–28  days as the pre-vaccination interval, 
Fig. 1 Pictorial presentation of the self-controlled case-series method applied in our study. Two possible scenarios for the timing of cardiovascular 
events (AMI or Stroke or Pulmonary embolism) and vaccination are shown. a Participant is followed from the start of the study period, has a 
CVD event at risk-period following vaccination. b Participant is followed from the start of the study period, has a CVD event at baseline following 
vaccination
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(4) 91–120  days and 121–180  days post vaccination 
period as part of the baseline period, and (5) both vac-
cinated and unvaccinated individuals during the defined 
study period.
In a separate analysis, we performed subgroup analysis 
by age (≥ 65 years versus < 65 years) for those at higher 
and lower cardiovascular risk. Finally, we performed 
stratified analyses among individuals defined as at higher 
risk by use of anti-platelets and anticoagulants (to deter-
mine if they would further modify risk).
Analyses were performed using Stata 16 software 
(StataCorp. 2016. Stata Statistical Software: Release 16. 
College Station, TX: StataCorp LP).
Results
We documented 5524 vaccinated individuals who suf-
fered an AMI, 3434 with a stroke, and 994 with pul-
monary embolism during the study period who were 
included in our analyses. Among them 495, 308, and 136 
individuals, respectively, were regarded as being at lower 
risk for cardiovascular events on the basis of their medi-
cation use history. Table 1 presents the general character-
istics of cases of AMI, stroke and pulmonary embolism 
identified during the study period. When we pooled the 
higher- and lower-risk groups together, we observed 
overall reduced relative risks for AMI, stroke and pulmo-
nary embolism following vaccination (Additional file  1: 
etable 1).
When we examined those aged 65  years and above 
and those below this age separately, the relative risks 
for AMI and stroke tended somewhat lower among 
those below 65  years than among those at 65 or above 
for the high-risk group (Additional file  1: etable  2). The 
results were generally similar for the two age groups 
among lower-risk individuals (Additional file 1: etable 3). 
When we performed analyses including 15–28  days or 
1–59  days pre-vaccination interval(s), the relative risks 
during this interval(s) for AMI, stroke and pulmonary 
embolism were relatively higher (Additional file  1: eta-
ble  4 and Additional file  1: etable  5) compared to the 
1–14 days pre-vaccination interval in the main analysis. 
Moreover, the results were similar to our main analyses 
when we considered 91–180  days post-vaccination as 
part of the baseline interval (Additional file  1: etable  5) 
and including both vaccinated and unvaccinated individ-
uals (results not shown).
Given that vaccination was associated with lower rela-
tive cardiovascular risk among individuals with higher 
baseline risk (Table  2), but the opposite among indi-
viduals with lower baseline risk (Table  3), we examined 
whether antithrombotic therapy (which was, by defini-
tion, restricted to those at higher risk) might modify 
the acute, potentially thrombosis-related risk associated 
with vaccination. Consistent with this hypothesis, users 
of anti-platelets had considerably lower relative risks for 
AMI and stroke, and users of anticoagulants had consid-
erably lower risks for pulmonary embolism than did non-
users (Tables 4, 5, respectively). When we performed the 
analyses stratifying anti-platelet users or anticoagulants 
users versus non-users (both antiplatelets and anticoag-
ulants), the results did not change (see Additional file 1: 
etable  6). When, instead of the season, we adjusted for 
daily mean temperature, the results were largely similar 
to the main analyses (results not shown).
Discussion
In this nationwide study, which included all Norwegian 
residents who sustained an AMI, stroke or pulmonary 
embolism within 180  days of a broadly recommended 
influenza vaccination, we observed a lower risk for all 
three cardiovascular events following vaccination among 
those at higher cardiovascular risk. This finding generally 
concords with previous studies, [5–7, 9–11, 26, 27] which 
included exclusively or predominantly high-risk individ-
uals. In our study, those taking antithrombotic medica-
tion appeared to benefit most clearly from vaccination. In 
contrast, among those having no prescribed cardiovas-
cular medication at baseline, vaccination appeared to be 
associated with acutely increased cardiovascular risk.
Few population-based studies have been able to 
assess the association between influenza vaccine and 
risk for AMI, stroke and pulmonary embolism among 
those at lower cardiovascular risk. This study was 
uniquely possible due to the special situation that 
occurred during the influenza A (H1N1) pandemic 
Table 1 Characteristics of the Study population
AMI acute myocardial infarction, SD standard deviation
a Only first-time AMI or Stroke or Pulmonary embolism cases occurring from 
May 1st, 2009 through 30th September 2010 or the day of emigration or death 
(whichever came first) were included
b Higher risk was defined as being registered in the Norwegian Prescription 
Database for any of the following drugs: anti-diabetic drugs, anti-obesity drugs, 
anti-thrombotic drugs, glycosides, anti-arrhythmic drugs, nitrates, beta-blockers, 
calcium channel blockers, anti-hypertensive drugs, diuretics, peripheral 
vasodilators or other vasodilators, drugs acting on the renin-angiotensin system, 
vasoprotective drugs, lipid modifying agents and drugs for obstructive airway 
diseases from 1st January 2004 until vaccination
c In absence of prescriptions to these drugs, we defined individuals as being at 
lower risk
AMIa Strokea Pulmonary 
 Embolisma
Total 5524 3434 994
Males, N (%) 3774 (68.3%) 1990 (57.9%) 510 (51.3%)
Higher-riskb, N (%) 5029 (91.0%) 3126 (91.1%) 859 (86.3%)
Lower-riskc, N (%) 495 (9.0%) 308 (8.9%) 136 (13.7%)
Mean age, years 67.2 (12.4) 69.9 (12.5) 63.4 (16.8)
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[19]. Contrary to preceding and subsequent years, in 
2009, the entire Norwegian population was advised to 
receive the vaccine, and vaccinations were easily availa-
ble through a public vaccination campaign. As a result, 
43% of the population was vaccinated [19]. In contrast, 
only around 10% of the population is vaccinated against 
influenza during ordinary seasons. [28]
Current guidelines across the globe generally empha-
size the importance of influenza vaccination among 
high-risk groups. [13–16] Before 2010, the Centers for 
Disease Control and Prevention in the US had a simi-
lar recommendation. However, a meeting of the Advi-
sory Committee on Immunization Practices changed 
this approach due to the fears of circulating H1N1 pan-
demic virus and because many were likely to be una-
ware of their high risk status [29]. Accordingly, the 
current recommendation in the US is to vaccinate all 
individuals aged 6 months and older [12].
In this study, we examined the risk for AMI, stroke 
and pulmonary embolism after an influenza vaccination 
among those at no apparent increased risk for cardiovas-
cular events based upon comprehensive drug registers. 
Our findings do not necessarily support the extension 
of vaccination to lower-risk individuals, at least for car-
diovascular prevention, as we found no cardiovascular 
benefit of the vaccine among those not taking no pre-
scribed cardiovascular medications. On the contrary, we 
unexpectedly found an increased risk for cardiovascular 
events after vaccination compared to the baseline period 
among these people. At the same time, it is likely that 
other benefits may exist from vaccination of lower-risk 
individuals, including fewer days of work lost due to ill-
ness and greater spread of herd immunity.
Our results concerning those whom we categorized as 
having low cardiovascular risk may reflect study design 
issues. As the SCCS is restricted to those with an event, 
Table 2 Incident rate  ratiosa, with 95% confidence intervals (CIs) for cardiovascular  eventsa following pandemic influenza 
vaccination (pandemrix) among higher risk individuals defined on the basis of medication use
AMI acute myocardial infarction, IRR incident rate ratio, CI confidence interval
a These are results from self-controlled case series analysis using data for first-time AMI (n = 5032), stroke (n = 3129) and pulmonary embolism (n = 859) patients who 
were vaccinated with Pandemrix. The start of observation period was May 1, 2009 and end of observation period was September 30, 2010 or the day of emigration 
or death (whichever came first). Person-time of each vaccinated individual was divided into following risk-periods: pre-vaccination interval (1–14 days prior to 
vaccination) and postvaccination intervals (1–14 days, 15–28 days, 29–59 days, 60–90 days, 91–120 days, 121–180 days following vaccination)
b All remaining part of the observation period was used for baseline comparison (unexposed person-time)
c Adjusted for calendar period (January–March, April–August, and September–December)





















3368 1,635,876 1.00 (ref.) 2061 1,017,036 1.00 (ref.) 564 279,612 1.00 (ref.)
Pre-vaccina-
tion interval
 1–14 days 124 70,686 0.85 (0.70–
1.02)
55 43,946 0.66 (0.50–
0.87)
30 12,082 1.23 (0.83–
1.81)
 On the day 
of vaccina-
tion
3 5049 0.29 (0.09–
0.89)
3 3139 0.50 (0.16–
1.56)
0 863 No estimates
Post vaccina-
tion interval
 1–14 days 105 70,686 0.72 (0.59–
0.88)
64 43,946 0.77 (0.59–
0.99)
18 12,082 0.73 (0.45–
1.19)
 15–28 days 101 70,686 0.70 (0.57–
0.85)
80 43,946 0.96 (0.76–
1.22)
22 12,082 0.89 (0.57–
1.38)
 29–59 days 277 156,519 0.88 (0.77–
1.00)
181 97,309 0.99 (0.84–
1.18)
49 26,753 0.86 (0.62–
1.20)
 60–90 days 261 156,519 0.87 (0.73–
1.04)
171 97,309 0.96 (0.77–
1.20)
39 26,753 0.65 (0.42–
1.00)
 91–120 days 293 141,470 1.01 (0.85–
1.20)
167 94,170 0.96 (0.78–
1.19)




500 302,940 0.82 (0.74–
0.91)
347 188,340 0.92 (0.82–
1.04)
88 51,780 0.81 (0.63–
1.04)
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and we only considered one event per individual, exclud-
ing those with medication use at the time of vaccination 
increases the likelihood that the event happens after vac-
cination as opposed to before, which in turn increases 
the relative risk. Moreover, the self-controlled case series 
method is susceptible to confounding by factors that vary 
within the individual. With a vaccination rate below 50%, 
vaccination was still somewhat selective, rather than 
truly universal, during this time period among lower-risk 
individuals. It is possible that a small number of these 
individuals were vaccinated specifically because their 
health was declining, leading to an artificially increased 
rate of events in the subsequent months. For this to be 
true, no similar decline could have been present among 
higher-risk individuals. Additional studies with access to 
detailed medical record data will be needed to evaluate 
this possibility.
On the other hand, if our findings reflect a true causal 
effect of the vaccine, the potential mechanism could be 
an alteration in the immune system following adjuvant-
boosted vaccination that might trigger hypercoagulabil-
ity—a common denominator for AMI, ischemic stroke 
and pulmonary embolism [30]. However, previous 
studies suggest that any such effect is likely be transient 
[31], while we observed an elevated risk even several 
months later. We can only speculate that, at least in a 
subset of susceptible individuals, vaccination might 
induce a more sustained effect. Of note, when we strati-
fied higher-risk individuals according to the use of anti-
thrombotic medication, those on anti-platelets were at 
considerably lower risk for AMI and stroke and those 
on anti-coagulants were at a considerably lower risk for 
pulmonary embolism than those not using these medi-
cations, respectively. These findings are consistent with 
the hypothesis that anti-platelets and anti-coagulants 
prevent coagulation in the high- and low-pressure parts 
of the circulatory system, respectively [32], although 
neither treatment can be recommended specifically to 
Table 3 Incident rate ratios, with 95% confidence intervals (CIs) for cardiovascular events following pandemic influenza 
vaccination (pandemrix) among lower risk individuals
These are results from self-controlled case series analysis using data for first-time AMI (n = 495), stroke (n = 308) and pulmonary embolism (n = 136) patients who were 
vaccinated with Pandemrix. The start of observation period was May 1, 2009 and end of observation period was September 30, 2010 or the day of emigration or death 
(whichever came first). Person-time of each vaccinated individual was divided into following risk-periods: pre-vaccination interval (1–14 days prior to vaccination) and 
postvaccination intervals (1–14 days, 15–28 days, 29–59 days, 60–90 days, 91–120 days, 121–180 days following vaccination)
AMI acute myocardial infarction, IRR incident rate ratio, CI confidence interva
a All remaining part of the observation period was used for baseline comparison (unexposed person-time)
b Adjusted for calendar period (January-March, April-August, and September-December)
AMI (n = 495) Stroke (n = 308) Pulmonary embolism (n = 136)
No. of events Person-days 
at risk














209 160,056 1.00 (ref.) 160 99,468 1.00 (ref.) 59 44,064 1.00 (ref )
Pre-vaccina-
tion interval
 1–14 days 2 6916 0.29 (0.07–
1.19)
4 4298 0.63 (0.23–
1.74)
1 1904 0.59 (0.08–
4.50)
 On the day 
of vaccina-
tion
– – No estimates – – No estimates – – No estimates
Post-vaccina-
tion interval
 1–14 days 29 6916 4.19 (2.69–
6.52)
11 4298 1.73 (0.90–
3.31)
4 1904 2.35 (0.78–
7.06)
 15–28 days 24 6916 3.17 (1.99–
5.07)
10 4298 1.51 (0.77–
2.97)
5 1904 2.61 (0.96–
7.08)
 29–59 days 43 15,314 2.28 (1.50–
3.49)
22 9517 1.40 (0.81–
2.42)
7 4216 1.40 (0.56–
3.52)
 60–90 days 57 15,314 2.78 (1.79–
4.32)
31 9517 1.86 (1.04–
3.32)
20 4216 3.43 (1.57–
7.47)
 91–120 days 46 14,820 2.27 (1.50–
3.44)
22 9210 1.37 (0.76–
2.46)




85 29,640 1.99 (1.54–
2.59)
48 18,420 1.54 (1.10–
2.17)
22 8160 1.80 (1.08–
3.00)
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prevent vaccination-related complications without fur-
ther clinical study.
Our study had several important limitations. Our most 
important limitation is that, contrary to some previous 
similar studies [5, 6, 10], we included only a single sea-
son in our analyses and variations in incidence of cardio-
vascular events occurring during the study period could 
have affected our estimates. However, it is unlikely that 
such variations affected lower- and higher-risk individu-
als differentially, and thus is unlikely to explain the clear 
contrast in observed risk after vaccination in these strata.
Stable characteristics like age, sex, education or chronic 
comorbidities that might affect both participation in the 
vaccination program and risk for cardiovascular events 
are not likely to explain the observed associations. We 
used SCCS analyses, and we performed within-person 
comparisons that implicitly control for unmeasured time-
invariant confounders. On the other hand, this design is 
not immune to the so-called immortal time bias, which 
may arise when a prerequisite to inclusion to the study 
is to survive until vaccination. This typically causes an 
upwards bias of estimates [33]. However, it is not clear 
how this bias, could explain the differential associations 
for lower- and higher-risk groups. This method only pro-
duces estimates of risk relative to an individual’s base-
line, which is likely to be quite modest among lower-risk 
individuals.
One of the assumptions of the SCCS is that the event of 
interest does not increase the probability of death. Car-
diovascular events are known to increase mortality, and 
thus this assumption was violated in our study. However, 
this could not possibly explain the marked difference in 
the observed effect of the vaccination among high- and 
low-risk individuals. Previous studies using SCCS to 
study the effects of influenza vaccination on risk for CVD 
events examined the size of the bias due this violation of 
assumptions and concluded that it is likely to be negligi-
ble [10, 34].
As cardiovascular events tend to cluster within the 
same individual, similar to previous studies, we disre-
garded repeated events during the follow up. However, 
this approach might have led to some, most probably 
minor, distortion of our results.
We utilized data from national registers. Registration 
of vaccination, dispensing of prescribed medications, 
and hospitalizations were mandatory, which ensured 
independent reporting and an unbiased assessment of 
the outcomes during follow up. The Norwegian Patient 
Registry has virtually complete coverage of medical 
and surgical care at hospitals and a generally high accu-
racy of diagnoses [23, 35]. To increase specificity, we 
restricted to cases with a primary diagnosis. In the Nor-
wegian Patient Registry, the primary diagnosis is given to 
the main reason for the patient’s need for treatment or 
investigation at a given hospitalization, and it has higher 
specificity than secondary diagnoses. On the other hand, 
our sensitivity was apt to be imperfect as we missed cases 
who died before arrival or, due to other reasons, were 
not treated at hospitals. However, specificity is generally 
a greater concern than sensitivity in similar settings [36].
Our definition of higher- and lower-cardiovascular risk 
had some limitations. We relied only on information on 
prescribed medications for conditions known to elevate 
cardiovascular risk. Therefore, the results for the lower-
risk individuals should be interpreted with caution in 
the absence of information on actual risk factor levels. 
Many may not receive any pharmaceutical treatment for 
such conditions, although, it should be emphasized that, 
in Norway, health care is equally available to all citizens 
irrespective of their income. Moreover, the Norwegian 
Prescription Database contains information only from 
pharmacies, and has no information on drugs given to 
institutionalized patients such as those in nursing homes.
Finally, it is not clear to what extent our results on use 
of Pandemrix during the H1N1 pandemic in 2009–2010 
generalizes to other seasons with different vaccines and 
different influenza strains.
Conclusion
This study confirms previous studies suggesting that 
patients at higher cardiovascular risk appear to ben-
efit from pandemic influenza vaccination. The protec-
tive effect of the vaccination was especially pronounced 
among those taking antithrombotic medication. How-
ever, our findings provide no support for a general rec-
ommendation of vaccination to everyone for prevention 
of cardiovascular outcomes. On the contrary, pandemic 
vaccination appeared to increase the acute risk of AMI, 
stroke and pulmonary embolism among those who were 
initially free of cardiovascular drugs. Further studies that 
are able to define lower- and higher-risk groups based on 
pre-existing diagnoses, rather than medications, would 
be of great relevance.
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